MEX3A and nasopharyngeal carcinoma: Moreover, treatment with an NF-κB signaling-specific inhibitor reversed the pro-oncogenic effects of MEX3A or SCIN overexpression in NPC cells, further suggesting that the NF-κB signaling pathway may be a downstream effector of the MEX3A/SCIN axis in NPC.